|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang J, Mani SA, Donaher JL, Ramaswamy S,
Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and
Weinberg RA: Twist, a master regulator of morphogenesis, plays an
essential role in tumor metastasis. Cell. 117:927–939. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tavazoie SF, Alarcón C, Oskarsson T, Padua
D, Wang Q, Bos PD, Gerald WL and Massagué J: Endogenous human
microRNAs that suppress breast cancer metastasis. Nature.
451:147–152. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pérez-Pomares JM and Muñoz-Chápuli R:
Epithelial-mesenchymal transitions: A mesodermal cell strategy for
evolutive innovation in Metazoans. Anat Rec. 268:343–351. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
She ZY and Yang WX: SOX family
transcription factors involved in diverse cellular events during
development. Eur J Cell Biol. 94:547–563. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hong CS and Saint-Jeannet JP: Sox proteins
and neural crest development. Semin Cell Dev Biol. 16:694–703.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Potzner MR, Tsarovina K, Binder E,
Penzo-Méndez A, Lefebvre V, Rohrer H, Wegner M and Sock E:
Sequential requirement of Sox4 and Sox11 during development of the
sympathetic nervous system. Development. 137:775–784. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Paul MH, Harvey RP, Wegner M and Sock E:
Cardiac outflow tract development relies on the complex function of
Sox4 and Sox11 in multiple cell types. Cell Mol Life Sci.
71:2931–2945. 2014. View Article : Google Scholar
|
|
13
|
Sun B, Mallampati S, Gong Y, Wang D,
Lefebvre V and Sun X: Sox4 is required for the survival of pro-B
cells. J Immunol. 190:2080–2089. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hu G and Chen J: A genome-wide regulatory
network identifies key transcription factors for memory
CD8+ T-cell development. Nat Commun. 4:28302013.
|
|
15
|
Zhang H, Alberich-Jorda M, Amabile G, Yang
H, Staber PB, Di Ruscio A, Welner RS, Ebralidze A, Zhang J,
Levantini E, et al: Sox4 is a key oncogenic target in C/EBPα mutant
acute myeloid leukemia. Cancer Cell. 24:575–588. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Medina PP, Castillo SD, Blanco S,
Sanz-Garcia M, Largo C, Alvarez S, Yokota J, Gonzalez-Neira A,
Benitez J, Clevers HC, et al: The SRY-HMG box gene, SOX4, is a
target of gene amplification at chromosome 6p in lung cancer. Hum
Mol Genet. 18:1343–1352. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bilir B, Osunkoya AO, Wiles WG IV,
Sannigrahi S, Lefebvre V, Metzger D, Spyropoulos DD, Martin WD and
Moreno CS: SOX4 is essential for prostate tumorigenesis initiated
by PTEN ablation. Cancer Res. 76:1112–1121. 2016. View Article : Google Scholar :
|
|
18
|
Liao YL, Sun YM, Chau GY, Chau YP, Lai TC,
Wang JL, Horng JT, Hsiao M and Tsou AP: Identification of SOX4
target genes using phylogenetic footprinting-based prediction from
expression microarrays suggests that overexpression of SOX4
potentiates metastasis in hepatocellular carcinoma. Oncogene.
27:5578–5589. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sinner D, Kordich JJ, Spence JR, Opoka R,
Rankin S, Lin SC, Jonatan D, Zorn AM and Wells JM: Sox17 and Sox4
differentially regulate beta-catenin/T-cell factor activity and
proliferation of colon carcinoma cells. Mol Cell Biol.
27:7802–7815. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yeh YM, Chuang CM, Chao KC and Wang LH:
MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis
by targeting SOX4 and HIF-1α. Int J Cancer. 133:867–878. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang J, Liang Q, Lei Y, Yao M, Li L, Gao
X, Feng J, Zhang Y, Gao H, Liu DX, et al: SOX4 induces
epithelial-mesenchymal transition and contributes to breast cancer
progression. Cancer Res. 72:4597–4608. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang L, Li Y, Yang X, Yuan H, Li X, Qi M,
Chang YW, Wang C, Fu W, Yang M, et al: ERG-SOX4 interaction
promotes epithelial-mesenchymal transition in prostate cancer
cells. Prostate. 74:647–658. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang C, Zhao H, Lu J, Yin J, Zang L, Song
N, Dong R, Wu T and Du X: Clinicopathological significance of SOX4
expression in primary gallbladder carcinoma. Diagn Pathol.
7:412012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Aaboe M, Birkenkamp-Demtroder K, Wiuf C,
Sørensen FB, Thykjaer T, Sauter G, Jensen KM, Dyrskjøt L and
Ørntoft T: SOX4 expression in bladder carcinoma: Clinical aspects
and in vitro functional characterization. Cancer Res. 66:3434–3442.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang J, Jiang H, Shao J, Mao R, Liu J, Ma
Y, Fang X, Zhao N, Zheng S and Lin B: SOX4 inhibits GBM cell growth
and induces G0/G1 cell cycle arrest through Akt-p53 axis. BMC
Neurol. 14:2072014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu J, Lamouille S and Derynck R:
TGF-beta-induced epithelial to mesenchymal transition. Cell Res.
19:156–172. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang T, Song W, Chen Y, Chen R, Liu Z, Wu
L, Li M, Yang J, Wang L2, Liu J, et al: Flightless I homolog
represses prostate cancer progression through targeting androgen
receptor signaling. Clin Cancer Res. 22:1531–1544. 2016. View Article : Google Scholar
|
|
28
|
Xu S, Tao Z, Hai B, Liang H, Shi Y, Wang
T, Song W, Chen Y, OuYang J, Chen J, et al: miR-424(322) reverses
chemoresistance via T-cell immune response activation by blocking
the PD-L1 immune checkpoint. Nat Commun. 7:114062016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen X, Ruan A, Wang X, Han W, Wang R, Lou
N, Ruan H, Qiu B, Yang H and Zhang X: miR-129–3p, as a diagnostic
and prognostic biomarker for renal cell carcinoma, attenuates cell
migration and invasion via downregulating multiple
metastasis-related genes. J Cancer Res Clin Oncol. 140:1295–1304.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huber MA, Kraut N and Beug H: Molecular
requirements for epithelial-mesenchymal transition during tumor
progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Guarino M, Rubino B and Ballabio G: The
role of epithelial-mesenchymal transition in cancer pathology.
Pathology. 39:305–318. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tiwari N, Tiwari VK, Waldmeier L, Balwierz
PJ, Arnold P, Pachkov M, Meyer-Schaller N, Schübeler D, van
Nimwegen E and Christofori G: Sox4 is a master regulator of
epithelial-mesenchymal transition by controlling Ezh2 expression
and epigenetic reprogramming. Cancer Cell. 23:768–783. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cho JH, Robinson JP, Arave RA, Burnett WJ,
Kircher DA, Chen G, Davies MA, Grossmann AH, VanBrocklin MW,
McMahon M, et al: AKT1 activation promotes development of melanoma
metastases. Cell Rep. 13:898–905. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kuo KT, Chen CL, Chou TY, Yeh CT, Lee WH
and Wang LS: Nm23H1 mediates tumor invasion in esophageal squamous
cell carcinoma by regulation of CLDN1 through the AKT signaling.
Oncogenesis. 5:e2392016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Niessner H, Forschner A, Klumpp B,
Honegger JB, Witte M, Bornemann A, Dummer R, Adam A, Bauer J,
Tabatabai G, et al: Targeting hyperactivation of the AKT survival
pathway to overcome therapy resistance of melanoma brain
metastases. Cancer Med. 2:76–85. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Larue L and Bellacosa A:
Epithelial-mesenchymal transition in development and cancer: Role
of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene.
24:7443–7454. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang PF, Li KS, Shen YH, Gao PT, Dong ZR,
Cai JB, Zhang C, Huang XY, Tian MX, Hu ZQ, et al: Galectin-1
induces hepatocellular carcinoma EMT and sorafenib resistance by
activating FAK/PI3K/AKT signaling. Cell Death Dis. 7:e22012016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Julien S, Puig I, Caretti E, Bonaventure
J, Nelles L, van Roy F, Dargemont C, de Herreros AG, Bellacosa A
and Larue L: Activation of NF-kappaB by Akt upregulates Snail
expression and induces epithelium mesenchyme transition. Oncogene.
26:7445–7456. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Grille SJ, Bellacosa A, Upson J,
Klein-Szanto AJ, van Roy F, Lee-Kwon W, Donowitz M, Tsichlis PN and
Larue L: The protein kinase Akt induces epithelial mesenchymal
transition and promotes enhanced motility and invasiveness of
squamous cell carcinoma lines. Cancer Res. 63:2172–2178.
2003.PubMed/NCBI
|
|
40
|
Talantov D, Mazumder A, Yu JX, Briggs T,
Jiang Y, Backus J, Atkins D and Wang Y: Novel genes associated with
malignant melanoma but not benign melanocytic lesions. Clin Cancer
Res. 11:7234–7242. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
de Bont JM, Kros JM, Passier MM,
Reddingius RE, Sillevis Smitt PA, Luider TM, den Boer ML and
Pieters R: Differential expression and prognostic significance of
SOX genes in pediatric medulloblastoma and ependymoma identified by
microarray analysis. Neuro Oncol. 10:648–660. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Huang YW, Liu JC, Deatherage DE, Luo J,
Mutch DG, Goodfellow PJ, Miller DS and Huang TH: Epigenetic
repression of microRNA-129–2 leads to overexpression of SOX4
oncogene in endometrial cancer. Cancer Res. 69:9038–9046. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yu CC, Chen PN, Peng CY, Yu CH and Chou
MY: Suppression of miR-204 enables oral squamous cell carcinomas to
promote cancer stemness, EMT traits, and lymph node metastasis.
Oncotarget. 7:20180–20192. 2016.PubMed/NCBI
|
|
44
|
Pramoonjago P, Baras AS and Moskaluk CA:
Knockdown of Sox4 expression by RNAi induces apoptosis in ACC3
cells. Oncogene. 25:5626–5639. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pan X, Zhao J, Zhang WN, Li HY, Mu R, Zhou
T, Zhang HY, Gong WL, Yu M, Man JH, et al: Induction of SOX4 by DNA
damage is critical for p53 stabilization and function. Proc Natl
Acad Sci USA. 106:3788–3793. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Moreno CS: The Sex-determining region
Y-box 4 and homeobox C6 transcriptional networks in prostate cancer
progression: Crosstalk with the Wnt, Notch, and PI3K pathways. Am J
Pathol. 176:518–527. 2010. View Article : Google Scholar :
|
